DivestmentMay 11, 2026, 06:36 AM
Certara Completes Medical Writing Business Divestment for $85M Cash
AI Summary
Certara, Inc. announced the completion of the sale of its global medical writing and related regulatory services business to Veristat, LLC for $85.0 million in cash, with additional contingent consideration. Concurrently, the company reported its first quarter 2026 financial results, showing a 1% increase in total revenue to $106.9 million but a net loss of $8.8 million, down from a net income of $4.7 million in the prior year. Certara also updated its full-year 2026 guidance to reflect the divestiture, expecting revenue between $395 million and $405 million.
Key Highlights
- Certara completed the sale of its global medical writing business to Veristat for $85.0M cash.
- An additional $15.0M is in escrow, with up to $35.0M contingent earn-out consideration.
- Q1 2026 revenue was $106.9M, a 1% increase from $106.0M in Q1 2025.
- Q1 2026 net loss was $8.8M, compared to a net income of $4.7M in Q1 2025.
- Q1 2026 adjusted EBITDA decreased 9% to $31.7M from $34.8M in Q1 2025.
- Software revenue grew 7% to $49.7M, while services revenue decreased 4% to $57.2M.
- Full year 2026 revenue guidance updated to $395M-$405M, including $18M from divested business.
- Full year adjusted diluted EPS guidance is $0.35-$0.41.